Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones

Kazutaka Aoki1,2, Haruhiro Sato1 and Yasuo Terauchi3

1) Internal Medicine, Kanagawa Dental University, Yokosuka, Japan
2) Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Abstract. Elevation of postprandial plasma glucose is correlated with an increase in cardiovascular events, and alpha-glucosidase inhibitors (αGIs) are effective at reducing postprandial glucose levels. In Japan, the αGIs acarbose, voglibose, and miglitol have been available since 1993, 1994, and 2006, respectively. Dipeptidyl peptidase-4 (DPP-4) inhibitors are also effective at reducing postprandial glucose levels, and they have been available in Japan since 2009. A combination therapy of αGI, miglitol, and the DPP-4 inhibitor, sitagliptin, is more effective at decreasing postprandial glucose levels than monotherapy with either miglitol or sitagliptin. Moreover, the combination therapy of miglitol and sitagliptin is more effective at increasing postprandial active glucagon-like peptide-1 (GLP-1) levels than monotherapy. Peptide YY (PYY) has appetite-suppressing and gastric-emptying effects similar to GLP-1. In healthy individuals, miglitol increases the postprandial total PYY; however, combination therapy of miglitol and vildagliptin does not change postprandial total PYY levels. αGIs are typically prescribed to be taken just before a meal, which can result in decreased drug adherence. Different patterns of αGI intake were examined, and the results showed that miglitol or acarbose administration after a meal is effective. The effects of taking miglitol dissolved in water during a meal appeared to be similar to that of taking miglitol as a tablet just before a meal. The long-term effects of taking miglitol dissolved in water should be evaluated in future studies. αGIs may be effective even when they are not taken before a meal, and a more flexible administration may improve drug adherence.

Key words: Alpha-glucosidase inhibitor, Dipeptidyl peptidase-4 inhibitor, Gut hormone, Intake pattern

A LARGE NUMBER OF PATIENTS have type 2 diabetes worldwide, including in Japan. Treatment is important as to prevent severe complications from diabetes. Elevation of postprandial plasma glucose levels is significantly correlated with an increase in cardiovascular events [1, 2]. Anti-diabetic drugs, such as alpha-glucosidase inhibitors (αGIs), dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides, GLP-1 analogs, and short-acting insulin, are effective at reducing postprandial glucose levels. We focused on αGIs and DPP-4 inhibitors, which are associated with incretin regulation.

In Japan, there are three types of approved αGIs: acarbose, voglibose, and miglitol. αGIs delay the absorption of glucose by inhibiting brush border enzymes in the small intestine, thereby decreasing postprandial plasma glucose and insulin levels [3]. DPP-4 inhibitors have been available in Japan since 2009, after which αGI use declined. However, αGIs are still important for the treatment of diabetes patients.

Miglitol reduces serum insulin levels and has anti-obesity effects [4]. The Study to Prevent Noninsulin-Dependent Diabetes Mellitus trial showed that acarbose therapy prevents progression to diabetes in individuals with impaired glucose tolerance (IGT) and reduces the risk of cardiovascular events compared with placebo [5]. Voglibose also reduces the development of type 2 diabetes in individuals with IGT [6]. Moreover, a meta-analysis of studies on type 2 diabetes (MeRIA7) revealed that acarbose reduces the risk of cardiovascular events compared with placebo [7].

DPP-4 inhibitors improve hyperglycemia by inhibiting cleavage of incretins. αGIs also affect incretins; therefore, the effect of combination therapy of an αGI and a DPP-4 inhibitor on gut hormones is interesting.

αGIs should be taken just before a meal according to
the package insert. However, this can result in decreased drug adherence. Allowing patients to take αGIs after a meal would create more flexibility of the timing of administration of αGIs and likely increase drug adherence. Therefore, it is important to determine the efficacy of αGIs when taken after a meal.

In this review, we aimed to analyze the effects of combination therapy of an αGI and a DPP-4 inhibitor on gut hormones. We also aimed to analyze patients’ levels of glycemic control based on the pattern of αGI intake. As αGIs have many beneficial effects, improving drug adherence should be considered in the timing of αGI administration to patients.

**Effect of Combination Therapy of αGI and DPP-4 Inhibitor on Gut Hormones**

**Summary of gut hormones**

Several gut hormones, secreted by the stomach or the small intestine, that regulate appetite and gastric emptying are shown in Table 1. Gut hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin. After food intake, GLP-1 is secreted by L cells located in the lower part of the small intestine, and GIP is secreted by K cells in the upper part of the small intestine. GLP-1 and GIP stimulate glucose-dependent insulin secretion; GLP-1 also inhibits glucagon secretion [8]. GLP-1 can reduce appetite and food intake and has a protective effect on the pancreatic β-cell function in animal models [8, 9]. GIP has additional effects on adipocytes and bone [8]. The peptide YY (PYY1–36) is mainly secreted by L cells in the intestine [10, 11]. Cleavage of the N-terminal tyrosine-proline residues of PYY1–36 by DPP-4 results in the production of PYY3–36, which constitutes approximately 63% of the total PYY after a meal and approximately 37% after fasting [12, 13]. PYY1–36 administration in mice and humans reduces food intake [14]. Cholecystokinin (CCK) is secreted from I cells in the duodenum and jejunum [15]. CCK stimulates pancreatic enzyme secretion and gall bladder contraction, and delays gastric emptying and food intake by stimulating the vagus nerve [16, 17]. Ghrelin is an orexigenic peptide secreted by the stomach [18]. Plasma ghrelin concentrations increase with fasting and decrease after eating [19]. Obestatin has been isolated from the rat stomach and is encoded by the ghrelin gene [20]. Obestatin reduces food intake and gastrointestinal motility; however, the effects of obestatin remain controversial [21, 22].

**Effect of αGIs or DPP-4 inhibitors on gut hormones**

Miglitol increases the GLP-1 secretion and decreases the GIP secretion [23-26]. These effects are due to a change in the location of glucose absorption from the upper portion to the lower portion of the small intestine. Kaku et al. reported that patients who received a single dose of miglitol showed higher postprandial plasma total PYY levels and lower postprandial active ghrelin levels after 180 min (% of basal levels) compared with the control group (no medication) [27]. Additionally, in the study by Kaku et al., miglitol suppressed appetite, maintained satiety, and delayed gastric emptying. Treatment with acarbose resulted in delays in gastric emptying and increase in CCK, GLP-1, and PYY levels [28].

DPP-4 inhibitors increase active GLP-1 and active GIP by inhibiting DPP-4 activity and improve hyperglycemia in a glucose-dependent fashion by increasing serum insulin and decreasing serum glucagon levels in patients with diabetes [29]. Administration of vildagliptin for 10 days decreased total PYY levels in patients with type 2 diabetes [30], and administration of sitagliptin for 3 months also reduced total PYY and PYY3–36 levels and increased PYY1–36 levels [31].Sitagliptin decreased the fasting total ghrelin levels in patients with type 2 diabetes, but did not change the postprandial total ghrelin levels in healthy individuals [32, 33]. Moreover, vildagliptin did not change the postprandial total ghrelin levels in patients with type 2 diabetes [34].

**Combination therapy of αGI and DPP-4 inhibitor**

**Human studies**

The specific changes in gut hormones that occur in individuals who received a combination of an αGI and a DPP-4 inhibitor have not been fully elucidated; therefore, the effects of αGIs, DPP-4 inhibitors, and combina-
dagliptin exhibited a non-significant decrease in serum
with the control group, whereas patients treated with vil‐
combination therapy, and the results were compared to those
lower than those in the control group, miglitol group, or
with the control group (Table 2). More specifically, com‐
plasma CCK, plasma active ghrelin, plasma obestatin,
intake [8], the increase of active GLP-1 may be benefi‐
tion therapy on gut hormones in healthy men were
Miglitol and sitagliptin were adminis‐
ted to healthy individuals as a single drug or as a com‐
therapy, and the results were compared to those
of the control group (no drug). The postprandial active
GLP-1 level was higher in the group treated with migli‐
tol, sitagliptin, and miglitol plus sitagliptin compared
with the control group (Table 2). More specifically, com‐
bination therapy of miglitol plus sitagliptin resulted in
higher postprandial active GLP-1 levels than monother‐
apy with miglitol or sitagliptin. The postprandial total
GIP levels in the miglitol plus sitagliptin group were
lower than those in the control group, miglitol group, or
sitagliptin group. As GLP-1 reduces appetite and food
intake [8], the increase of active GLP-1 may be beneficial
for obese patients with type 2 diabetes. However, the
exact effects of increased active GLP-1 after combina‐
tion therapy in diabetes patients remain unknown; there‐
fore, further research is needed to study this aspect.

Subsequently, the effect of another combination ther‐
apy of an αGI and a DPP-4 inhibitor on gut hormones,
such as total PYY (PYY_{3-36}, plus PYY_{3-36}), CCK, ghre‐
lin, and obestatin, were evaluated (Table 2) [36]. Miglitol
and vildagliptin were administered to healthy men either
as monotherapy or combination therapy, and the results
were compared to those of the control group (no drug).
The postprandial serum total PYY was significantly
increased in the group treated with miglitol compared
with the control group, whereas patients treated with vil‐
dagliptin exhibited a non-significant decrease in serum
total PYY compared with the control group. As expected,
the serum total PYY levels of patients treated with
combination therapy remained unchanged compared
with the control group. In addition, the postprandial
plasma CCK, plasma active ghrelin, plasma obestatin,
and ghrelin/obestatin levels of patients who received
combination therapy remained unchanged compared
with the control group. These results suggested that
combination therapy of miglitol and vildagliptin has no effect
on appetite-regulating hormones, such as total PYY,
CCK, active ghrelin, and obestatin. In the future, it will
be interesting to study the appetite and gastric emptying
of patients with type 2 diabetes after receiving a combi‐
nation therapy.

Mikada et al. reported on the use of combination ther‐
apy of miglitol and sitagliptin for 24 weeks in over‐
weight patients with type 2 diabetes [26]. Postprandial
active GLP-1 levels of patients treated with combination
therapy after a meal tolerance test were increased com‐
pared with those treated with miglitol or sitagliptin. Post‐
prandial total GIP was decreased after treatment with
miglitol, but remained unchanged after treatment with
sitagliptin. Additionally, combination therapy was more
effective in decreasing total GIP than monotherapy with
miglitol or sitagliptin.

We also reported the effectiveness of the miglitol
monotherapy when received just before breakfast on the
plasma glucose and incretin levels in sitagliptin-treated
patients with type 2 diabetes [37]. Miglitol was not
administered on the first day; it was only administered
on the second day just before breakfast. Miglitol was
only administered just before breakfast, but was not
administered before lunch in order to increase the post‐
prandial active plasma GLP-1 levels after lunch. This
finding suggests that miglitol, in combination with sita‐
gliptin, can act as a “GLP-1 enhancer,” even in combina‐
tion with sitagliptin. As mentioned previously, the effects
of high active GLP-1 levels in diabetes patients treated
with combination therapy remain unknown.

**Animal studies**

db/db mice, an animal model of diabetes, were under
combination therapy with voglibose and alogliptin for 3
weeks [38]. The combination therapy increased insulin
and active GLP-1 secretion, decreased glucagon secre‐
tion, prevented the onset of diabetes, and preserved pan‐
creatic beta-cell in prediabetic db/db mice. The authors
suggested that these effects were due to the increased
active GLP-1 levels and improved hyperglycemia by the
combination therapy. Combination therapies of three dif‐
f erent αGIs (acarbose, voglibose, or miglitol) and sita‐
gliptin were administered to C57BL/6J mice [39], and all
three combinations resulted in a synergic increase of
active GLP-1. The combination therapy of miglitol and sitagliptin resulted in a stronger inhibition of early phase of postprandial hyperglycemia compared with other combinations.

**Combination therapy of αGI and other antidiabetic drugs**

The combination therapy of miglitol and metformin improved the glycemic control of patients with type 2 diabetes compared with metformin monotherapy [40]. The combination therapy of miglitol and mitiglinide also improved the glycemic control of patients with type 2 diabetes compared with monotherapy [41]. The addition of dulaglutide to the αGI treatment resulted in a decrease in HbA1c levels and body weight [42]. The combination therapy of premixed insulin and acarbose or metformin improved the glycemic control of the patients with type 2 diabetes to some extent [43]. Thus, the combination of αGI and other antidiabetic drugs is also effective in improving glycemic control. In addition to αGI and DPP-4 inhibitor, metformin can also increase endogenous active GLP-1 levels in the patients with type 2 diabetes [44]. However, it remains unclear whether a combination of αGI and metformin is more effective in increasing active GLP-1 levels than monotherapy. As the effects of αGI and DPP-4 inhibitor combination therapy on incretin levels have already been validated, those of αGI and metformin combination therapy should also be investigated in future studies.

![Intake Pattern of αGI](image)

**Fig. 1** The effects of miglitol intake pattern on postprandial plasma glucose levels

Miglitol was administered once using four different intake patterns. Control: no miglitol, intake 1: just before breakfast, intake 2: 15 min after the beginning of breakfast, intake 3: 30 min after the beginning of breakfast. **A**: Effects of the intake patterns on plasma glucose levels from mealtime (0 min) to 180 min after the meal. **B**: The area under the curve (AUC) of plasma glucose from 0 min to 180 min after the meal. *p < 0.05 compared with the control group.

**Intake Pattern of αGI**

**Administration of αGI after a meal**

In Japan, patients with type 2 diabetes are instructed to take αGI just before a meal; however, it is often difficult to take these drugs just before a meal. A gastric emptying test was conducted in patients with diabetes using a 99mTc-labeled solid meal. The mean gastric retention rates at 150 min after starting the meal in patients without or with autonomic neuropathy were 33% and 65%, respectively [45]. Therefore, αGI is effective in patients with diabetes when administered after a meal. Rosac *et al.* reported that acarbose is effective in type 2 diabetes patients when taken 15 min after starting a meal [46]. Asakura *et al.* reported that acarbose is effective in healthy or IGT individuals when taken 30 min after starting a meal [47]. Miglitol is partially absorbed at the upper portion of the small intestine, resulting in a higher effectiveness at reducing blood glucose levels at 30 min after a meal than voglibose or acarbose [48, 49]. Therefore, it was interesting to examine the effect of miglitol treatment after a meal in patients with type 2 diabetes. As shown in Fig. 1, administration of miglitol at 15 and 30 min after the start of a meal decreased the postprandial glucose levels to the same extent as when miglitol was administered just before a meal [50]. Another study showed that the administration of miglitol after meals for a duration of 3 months decreased the HbA1c level and increased the 1,5-anhydroglucitol (1,5-AG) level to the same extent as when miglitol was administered just before a meal [51]. The effect of a single administration of voglibose just after a meal was also evaluated in indi-
individuals with or without IGT [52]. The administration of voglibose just before breakfast decreased the postprandial plasma glucose levels, but the administration of voglibose after a meal did not decrease the postprandial plasma glucose levels. It was reported that the administration of voglibose after a meal tends to decrease postprandial serum insulin levels ($p = 0.07$). Hence, a long-term observational study using a larger sample size is required to further evaluate the effects of administering voglibose after a meal. In summary, administration of miglitol or acarbose after a meal is effective and this may improve drug adherence of patients with diabetes.

**Dissolved-dose regimen of αGI**

The administration of miglitol after a meal decreased the postprandial plasma glucose to the same level as administration just before a meal; therefore, it was evaluated whether a divided-dose of miglitol might improve postprandial glucose excursions. Administration of a divided-dose of miglitol just before and 15 min after the start of a meal smoothed the postprandial glucose and insulin excursions in healthy men [53].

More recently, the efficacy and safety of miglitol dissolved in water during a meal and a miglitol tablet taken just before a meal were compared [54]. Postprandial plasma glucose and insulin levels were significantly lower when miglitol was taken just before breakfast and when miglitol dissolved in water was consumed during breakfast compared with not taking the medication at all. The efficacy of taking miglitol dissolved in water during a meal appeared to be similar to taking a miglitol tablet just before a meal. Interestingly, the coefficient of variation of plasma glucose was significantly lower for the dissolved-dose regimen than taking miglitol just before a meal or not taking miglitol at all. Therefore, the results of this study suggest that a dissolved-dose regimen is useful, but longer effects of taking miglitol dissolved in water on glycemic control need to be studied further.

**Summary**

In this review, we described the effects of combination therapy of αGIs and DPP-4 inhibitors on gut hormones. The combination therapy of miglitol and sitagliptin increases active GLP-1 levels. As the exact effects of increased active GLP-1 levels after combination therapy in diabetes patients are unknown, further studies are warranted to examine the effects of combination therapy on other gut hormones.

In addition, we evaluated the effect of intake pattern of αGIs on glycemic control. The administration of miglitol or acarbose after a meal is effective, and this may improve the drug adherence of patients with diabetes. The effects of drinking water with dissolved miglitol during a meal appeared similar to taking a miglitol tablet just before a meal. Thus, we propose the possible usefulness of this dissolved-dose regimen, and the long-term effects of taking miglitol dissolved in water should be evaluated.

In conclusion, miglitol increases GLP-1 levels even in combination with sitagliptin. Improving drug adherence should be considered when discussing the intake pattern of αGIs with patients.

**Acknowledgements**

This work was supported by Grants-in-Aid for Scientific Research (C) 16K09806 (to K. A.), (B) 21390282, (B) 24390235, and (B) 16H05329 (to Y. T.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and a Medical Award from the Japan Medical Association (to Y. T.).

**Disclosure**

Terauchi Y received honoraria for lectures from MSD; Ono Pharmaceutical Co. Ltd.; Boehringer Ingelheim GmbH; Takeda Pharmaceutical Company Ltd.; Tanabe-Mitsubishi Pharma; Daiichi-Sankyo Company Ltd.; Sanwa Kagaku Kenkyusho Co., Ltd.; Novo Nordisk Pharma Ltd.; Eli Lilly and Company; Sanofi; DaiNippon-Sumitomo; Shionogi & Co., Ltd.; Bayer Yakuhin Ltd.; Astellas Pharma Inc.; and Astra Zeneca and obtained research support from MSD; Ono Pharmaceutical Co. Ltd.; Boehringer Ingelheim GmbH; Takeda Pharmaceutical Company Ltd.; Tanabe-Mitsubishi Pharma; Daiichi-Sankyo Company Ltd.; Sanwa Kagaku Kenkyusho Co., Ltd.; Novo Nordisk Pharma Ltd.; Eli Lilly and Company; Sanofi; Astellas Pharma Inc.; and Astra Zeneca. Aoki K obtained research support from Sanwa Kagaku Kenkyusho Co., Ltd.

**References**

1. The DECODE study group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. *Lancet* 354: 617–621.

2. DECODE study group (2002) Cardiovascular risk profile assessment in glucose-intolerant Asian individuals—an evaluation of the World Health Organization two-step
strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia). *Diabet Med* 19: 549–557.

3. Joshi SR, Standl E, Tong N, Shah P, Kalra S, et al. (2015) Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. *Expert Opin Pharmacother* 16: 1959–1981.

4. Sugimoto S, Nakajima H, Kosaka H, Hosoi H (2015) Review: miglitol has potential as a therapeutic drug against obesity. *Nutr Metab (Lond)* eCollection 12: 51.

5. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 359: 2072–2077.

6. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, et al. (2009) Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. *Lancet* 373: 1607–1614.

7. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, et al. (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. *Eur Heart J* 25: 10–16.

8. Nauck MA, Meier JJ (2018) Incretin hormones: their role in health and disease. *Diabetes Obes Metab* 20 Suppl 1: 5–21.

9. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, et al. (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. *Endocrinology* 143: 4397–4408.

10. Tatemoto K, Mutt V (1980) Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. *Nature* 285: 417–418.

11. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, et al. (1985) Human distribution and release of a putative new gut hormone, peptide YY. *Gastroenterology* 89: 1070–1077.

12. Ballanytne GH (2006) Peptide YY(1–36) and peptide YY(3–36): Part I. Distribution, release and actions. *Obes Surg* 16: 651–658.

13. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, et al. (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36. *Regul Pept* 51: 151–159.

14. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, et al. (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. *Nature* 418: 650–654.

15. Polak JM, Bloom SR, Rayfoud PL, Peare AG, Buchan AM, et al. (1975) Identification of cholecystokinin-secreting cells. *Lancet* 2: 1016–1018.

16. Wren AM, Bloom SR (2007) Gut hormones and appetite control. *Gastroenterology* 132: 2116–2130.

17. Berthoud HR (2008) The vagus nerve, food intake and obesity. *Regul Pept* 149: 15–25.

18. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 402: 656–660.

19. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. *Diabetes* 50: 1714–1719.

20. Zhang JY, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, et al. (2005) Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. *Science* 310: 996–999.

21. Xing YX, Yang L, Kuang HY, Gao XY, Liu HL (2017) Function of obestatin in the digestive system. *Nutrition* 34: 21–28.

22. Cowan E, Burch KJ, Green BD, Grieve DJ (2016) Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes. *Br J Pharmacol* 173: 2165–2181.

23. Aoki K, Miyazaki T, Nagakura J, Orime K, Tobashi Y, et al. (2010) Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. *Endocr J* 57: 673–677.

24. Masuda K, Aoki K, Terauchi Y (2011) Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance. *J Diabetes Investig* 2: 435–440.

25. Narita T, Katsuraya Y, Sato T, Hosoba M, Fujita H, et al. (2009) Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. *Diabet Med* 26: 187–188.

26. Mikada A, Narita T, Yokoyama H, Yamashita R, Horikawa Y, et al. (2014) Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in overweight Japanese patients with type 2 diabetes. “the MASTER randomized, controlled trial”. *Diabetes Res Clin Pract* 106: 538–547.

27. Kaku H, Tajiri Y, Yamada K (2012) Anorexigenic effects of miglitol in concert with the alterations of gut hormone secretion and gastric emptying in healthy subjects. *Horm Metab Res* 44: 312–318.

28. Enç FY, Imeryüz N, Akin L, Turoğlu T, Dede F, et al. (2001) Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. *Am J Physiol Gastrointest Liver Physiol* 281: G752–G763.

29. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, et al. (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. *Eur Heart J* 25: 10–16.

30. Kurzer C, Bock G, Giesler PD, Burton DB, Serra DB, et al. (2008) The effect of dipeptidyl peptidase-4 inhibition on
effects of alpha-glucosidase inhibitor

Patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. *Endocr J* 62: 1101–1114.

43. Wu H, Liu J, Lou Q, Liu J, Shen L, *et al.* (2017) Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus. *Medicine (Baltimore)* 96: e7533.

44. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, *et al.* (2004) Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. *Diabetes Nutr Metab* 17: 336–342.

45. Hayashi Y, Hongo M, Satake K, Toyota T, Goto Y, *et al.* (1987) Gastric emptying in patients with diabetes. *Nihon Shokakibyo Gakkai Zasshi* 84: 1–5 (In Japanese).

46. Rosak C, Nitzsche G, Konig P, Hofmann U (1995) The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. *Diabet Med* 12: 979–984.

47. Asakura T, Seino H, Nozaki S, Suzuki Y, Abe R (1999) Effect of acarbose taken just before and after a meal on plasma glucose level in Japanese healthy subjects. *Jpn J Hosp Pharm* 25: 715–720.

48. Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, *et al.* (2012) Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. *Diabetes Obes Metab* 14: 283–287.

49. Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, *et al.* (2008) Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. *Metabolism* 57: 1299–1306.

50. Aoki K, Nakamura A, Ito S, Nezu U, Iwasaki T, *et al.* (2007) Administration of miglitol just before and after a meal in patients with type 2 diabetes treated with sitagliptin. *Acta Diabetol* 49: 225–230.

51. Horikawa Y, Enya M, Izuaka K, Chen GY, Kawachi S, *et al.* (2011) Synergistic effect of alpha-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment. *J Diabetes Invest* 2: 200–203.

52. Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group (2001) The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. *Diabetes Care* 24: 989–994.

53. Tatsumi F, Hashiramoto M, Hirukawa H, Kimura T, Shimoda M, *et al.* (2013) Concomitant use of miglitol and metformin as initial combination therapy in type 2 diabetes mellitus. *Diabetes Res Clin Pract* 101: 35–44.

54. Shimata E, Aoki K, Tajima K, Taguri M, Terauchi Y (2016) Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes. *Expert Opin Pharmacother* 17: 889–894.